Tolperison (Tolpermyo®)

The National Health Care Institute has drawn up a pharmacotherapeutic report for the medicine tolperison (Tolpermyo®), whereby it reached the following conclusion. Based on the criteria of the Medicines Reimbursement System (GVS), the National Health Care Institute is of the opinion that tolperison is interchangeable with baclofen and tizanidine, and can therefore be included on List 1A of the GVS in cluster 0M03BXAV with a standard dose of 200 mg/day.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.